Michael Bretherton

Michael Anthony Bretherton is Chief Executive Officer & Executive Director at Sarossa Plc.
He is Chairman at Adams Plc since 2015 and Chairman at Hardy Plc since 2020.
He serves as Director at ORA Capital Partners Ltd., Blake Holdings Ltd., and Blake Holdings Ltd. (Jersey).
He is an Independent Non-Executive Director at e-Therapeutics Plc since 2023.
He is a Member of The Institute of Chartered Accountants in England & Wales.
Former roles include Executive Chairman & Finance Director at Oxeco Plc (2009–2010) and Sarossa Capital Ltd. (2014–2017).
Non-Executive Director at Ceres Power Holdings plc (2012–2013).
Director-Financial Operations at Mapeley Estates Ltd. Finance Director at ORA Capital Partners Ltd. (2006–2014).
Director at Woodbois Services Ltd (2007–2013), Bridgend Group Plc, Kanyon Plc, Oxray Ltd., AlbR Capital Ltd., Nanoco Technologies Ltd., Oxford Nutra Ltd., Novum Private Clients Ltd., Novum Nominees Ltd., Abway Enterprises Corp., Ora Capital Services Ltd., and ORA Ltd. Independent Non-Executive Director at ChemAI Ltd. (2012–2013) and Finance Director, Secretary & Director at ChemAI Ltd. (2015–2019).
Non-Executive Director at Nanoco Group Plc (2010–2014).
Director & Finance Director at Woodbois Ltd. (2012–2013).
Executive Director & Finance Director at Abaco Capital Plc (2012–2013).
Secretary, Director & Finance Director at Tissue Regenix Group Plc (2011).
Director at Oxford Pharmascience Ltd. (2009–2013).
Manager & Accountant at PricewaterhouseCoopers LLP (United Kingdom).
Corporate Financial Manager at The Plessey Co. Plc.
Education includes an undergraduate degree from the University of Leeds, conferred in 1978.